Literature DB >> 26277097

Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Hei Jason Chan1, Karineh Petrossian1, Shiuan Chen2.   

Abstract

Aromatase and estrogen receptor α (ER) are two key proteins for the proliferation of endocrine-responsive and -resistant breast cancers. Aromatase is an enzyme involved in the conversion of androgen (such as testosterone) to estrogen (such as 17β-estradiol). It is also a very effective therapeutic target for the treatment of endocrine-responsive breast cancer. Comparing endocrine-responsive and -resistant breast cancer, aromatase protein levels do not change significantly. Aromatase activity; however, can be increased via PI3K/Akt/IGFR signaling pathways in endocrine resistant cells. The activity of aromatase has been reported to be modulated by phosphorylation. The ER is an important steroid nuclear receptor in the proliferation of both endocrine-responsive and -resistant cells. Although the mutation or amplification of ER can cause endocrine resistance, it is not commonly found. Some point mutations and translocation events have been characterized and shown to promote estrogen-independent growth. Phosphorylation by cross-talk with growth factor pathways is one of the main mechanisms for ligand-independent activation of ER. Taken together, both ER and aromatase are important in ER-dependent breast cancer and the development of endocrine resistance.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aromatase; Aromatase inhibitor resistance; Breast cancer; Estrogen receptor α

Mesh:

Substances:

Year:  2015        PMID: 26277097      PMCID: PMC4752924          DOI: 10.1016/j.jsbmb.2015.07.018

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  164 in total

Review 1.  The role of estrogen receptor-β in breast cancer.

Authors:  Leigh C Murphy; Etienne Leygue
Journal:  Semin Reprod Med       Date:  2012-01-23       Impact factor: 1.303

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

Review 3.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

4.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors:  J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

5.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Authors:  J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

6.  Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.

Authors:  J R Pasqualini; G Chetrite; C Blacker; M C Feinstein; L Delalonde; M Talbi; C Maloche
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

7.  A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.

Authors:  S E Bulun; T M Price; J Aitken; M S Mahendroo; E R Simpson
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

8.  A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.

Authors:  Ramon Colomer; Mariano Monzo; Ignasi Tusquets; Juli Rifa; José M Baena; Agusti Barnadas; Lourdes Calvo; Francisco Carabantes; Carmen Crespo; Montserrat Muñoz; Antonio Llombart; Arrate Plazaola; Rosa Artells; Monstsrrat Gilabert; Belen Lloveras; Emilio Alba
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

9.  A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.

Authors:  Laura Maffei; Vincenzo Rochira; Lucia Zirilli; Paula Antunez; Claudio Aranda; Bibiana Fabre; Maria L Simone; Elisa Pignatti; Evan R Simpson; Souheir Houssami; Colin D Clyne; Cesare Carani
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-04       Impact factor: 3.478

Review 10.  Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development.

Authors:  Bramanandam Manavathi; Venkata S K Samanthapudi; Vijay Narasimha Reddy Gajulapalli
Journal:  Front Cell Dev Biol       Date:  2014-08-12
View more
  13 in total

Review 1.  Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.

Authors:  Xi Zhang; Nadia Harbeck; Udo Jeschke; Sophie Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-26       Impact factor: 4.553

Review 2.  Regulation of aromatase in cancer.

Authors:  Deborah Molehin; Fahmida Rasha; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Mol Cell Biochem       Date:  2021-02-18       Impact factor: 3.396

Review 3.  Skeletal muscle wasting: the estrogen side of sexual dimorphism.

Authors:  Shawna L McMillin; Everett C Minchew; Dawn A Lowe; Espen E Spangenburg
Journal:  Am J Physiol Cell Physiol       Date:  2021-11-17       Impact factor: 4.249

4.  Regulation of Estradiol Synthesis by Aromatase Interacting Partner in Breast (AIPB).

Authors:  Himangshu S Bose; Randy M Whittal; Curtis E Lanier; Brendan Marshall; Maheshinie Rajapaksha; Brian W Wheeler; Nicholas D Carbo; Elin M Hahn; Elizabeth W Perry; Neal M Hall; Mikhail M Melomed; Edward L Perkins; William E Burak
Journal:  Mol Cell Biol       Date:  2021-08-30       Impact factor: 4.272

Review 5.  Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein.

Authors:  Pulak R Manna; Ahsen U Ahmed; Deborah Molehin; Madhusudhanan Narasimhan; Kevin Pruitt; P Hemachandra Reddy
Journal:  Biomedicines       Date:  2022-06-03

Review 6.  Current physico-biochemistry in steroid research and status of structural biology for steroid-converting enzymes.

Authors:  S X Lin; R Shi; X J Hu; T M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-16       Impact factor: 4.292

7.  Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.

Authors:  Maria da Conceição Barros-Oliveira; Danylo Rafhael Costa-Silva; Alesse Ribeiro Dos Santos; Renato Oliveira Pereira; José Maria Soares-Júnior; Benedito Borges da Silva
Journal:  Clinics (Sao Paulo)       Date:  2021-06-14       Impact factor: 2.365

Review 8.  Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.

Authors:  Erik Hilborn; Olle Stål; Agneta Jansson
Journal:  Oncotarget       Date:  2017-05-02

Review 9.  Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.

Authors:  Alma D Campos-Parra; Eduardo López-Urrutia; Luz Tonantzin Orozco Moreno; César López-Camarillo; Thuluz Meza-Menchaca; Gabriela Figueroa González; Lilia P Bustamante Montes; Carlos Pérez-Plasencia
Journal:  Int J Mol Sci       Date:  2018-09-11       Impact factor: 5.923

10.  ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.

Authors:  Karineh Petrossian; Noriko Kanaya; Chiao Lo; Pei-Yin Hsu; Duc Nguyen; Lixin Yang; Lu Yang; Charles Warden; Xiwei Wu; Raju Pillai; Lauren Bernal; Chiun-Sheng Huang; Laura Kruper; Yuan Yuan; George Somlo; Joanne Mortimer; Shiuan Chen
Journal:  Oncotarget       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.